SCHEMBL352483

SCHEMBL352483

O=C(O)c1ncncc1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.45
HCAR2 Q8TDS4 3/20 0.44
KDM4E B2RXH2 3/20 0.35
NAPRT Q6XQN6 1/20 0.35
KMO O15229 4/20 0.34
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
TSHR P16473 2/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
BLM P54132 1/20 0.33
AGER Q15109 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ASPH Q12797 1/20 0.31
KDM8 Q8N371 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055362 0.80 SPR (0.44) SPRHCAR2KDM4EALDH1A1MAPT
SCHEMBL30978924 0.77 HCAR2 (0.44) SPRHCAR2KDM4ENAPRTKMO
SCHEMBL68960 0.77 KDM4E (0.47) HCAR2KDM4ENAPRTALDH1A1MAPT
SCHEMBL629032 0.77 HCAR2 (0.44) SPRHCAR2KDM4ENAPRTKMO
SCHEMBL31444812 0.76 MEN1 (0.46) HCAR2KDM4ENAPRTKMOALDH1A1
SCHEMBL13758658 0.76 HCAR2 (0.43) SPRHCAR2KDM4ENAPRTKMO
SCHEMBL29957082 0.76 HCAR2 (0.43) HCAR2KDM4ENAPRTKMOALDH1A1
SCHEMBL9278316 0.76 MEN1 (0.46) HCAR2KDM4ENAPRTKMOALDH1A1
SCHEMBL20928646 0.76 HCAR2 (0.43) SPRHCAR2KDM4ENAPRTKMO
SCHEMBL3567228 0.76 KDM4E (0.44) HCAR2KDM4ENAPRTKMOALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102414190-B Inhibitors of NF-kB PROFECTUS BIOSCIENCES INC 2015-06-03 CN disclosed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
CN-102414190-A Inhibitors of NF-kB PROFECTUS BIOSCIENCES INC 2012-04-11 CN disclosed
EP-2411376-A1 INHIBITORS OF NF-KB Profectus Biosciences, Inc. (US) 2012-02-01 EP disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed
WO-2010111460-A1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG SPR 3504/4885HCAR2 2564/4885KDM4E 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.